Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESTO trial
2022-001752-42Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Dec 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, oxaliplatin, folinic acid, fluorouracil and docetaxel in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Clinical and pathological complete response rate at endoscopic re-evaluation. Started Dec 2022; status: active.
02
Drugs
durvalumaboxaliplatinfolinic acidfluorouracildocetaxel
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2022-001752-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001752-42.